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The hypothesis that bone
turnover influences FGF23
secretion
To the Editor: Fibroblast growth factor 23 (FGF23) regulates
serum phosphate (Pi) levels. Isakova et al.1 commented on
a blueprint for randomized trials targeting phosphorus
metabolism in chronic kidney disease. In this review, Isakova
et al. revealed that Pi levels were normal to high in secondary
syndromes of FGF23 excess, such as kidney disease; however,
the levels were low in ‘primary’ syndromes of FGF23 excess,
such as the hereditary diseases (X-linked hypophosphatemia,
autosomal dominant hypophosphatemic rickets, autosomal
recessive hypophosphatemic rickets), and tumor-induced
osteomalacia. With decrease in renal function, the serum
FGF23 level is elevated; however, the phosphorus excretion
decreases. Osteitis ﬁbrosa progresses at the same time. FGF23
was secreted by osteocytes.2 Therefore, we drew up the
hypothesis that bone turnover inﬂuences FGF23 secretion.
We had reported previously the response of phosphorus load
to osteoprotegerin (OPG) knockout (KO) mice (Figure 1).
FGF-23 expression was signiﬁcantly increased by a high-
phosphate diet in wild-type (WT) mice, but not in OPG KO
mice. NaPi2a messenger RNA expression in kidney was
suppressed in WT mice receiving a high-phosphate diet, but
suppression was less marked in OPG KO mice. Therefore,
OPG may have a key role in mediating the response of FGF-
23 to an oral phosphate load in bone cells.3 When we evaluate
the metabolism of FGF23, it is necessary to consider the
structural change in the osteitis ﬁbrosa.
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The Authors Reply: We agree with Ohkido et al.1 that
osteocytes likely have a critical role in ﬁbroblast growth
factor (FGF)23 regulation in chronic kidney disease (CKD).
In addition to the supportive ﬁndings from their animal
studies outlined in ‘The hypothesis that bone turnover
inﬂuences FGF23 secretion,’ recent human studies have
shown that FGF23 expression in bone is already elevated in
the early stages of CKD.2 Moreover, emerging data on the
structure and function of osteocytes, their dendritic processes,
and surrounding capillary networks have provided further
support for the existence of a bone–kidney axis.3 Future
explorations of this hypothesis are likely to yield signiﬁcant
new insights into bone physiology and regulation of phos-
phorus metabolism and, ideally, the discovery of novel
therapeutic targets for various bone and mineral illnesses.
However, assessments of bone disease with bone biopsies in
the large-scale randomized trials we propose would increase
the complexity of trial design and diminish feasibility, and
http://www.kidney-international.org l e t te r to the ed i to r
& 2010 International Society of Nephrology
% Tubular reabsorption of phosphate (%TRP)
NS
P<0.05
P<0.05
P<0.05
%
 T
RP
100
90
80
70
60
50
40
30
20
10
0
WT/
normal diet
OPG KO/
normal diet
OPG KO/
high-P diet
WT/
high-P diet
Figure 1 |Percentage tubular reabsorption of phosphate (%TRP). Percentage TRP levels of the wild-type (WT)/high-phosphate diet
group are significantly lower than those of the WT/normal-diet group. In the osteoprotegerin/high-phosphate (OPG KO/high-P) group, they
are significantly lower than in the OPG KO/normal-diet group, but the reduction rate is significantly lower in OPG KO mice than in WT mice.
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therefore these measurements were not included in the
blueprint.4
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Assessment of acid–base disorders
To the Editor: Adrogue´ et al.1 give an overview of the three
distinct approaches that are currently used in assessing
acid–base disorders. In contrast to their assumption that the
chloride level is normal in high anion gap acidosis (Table 2),
there is often a low plasma chloride level because the plasma
chloride decreases relative to sodium in these cases.2 They
also assume that there is no signiﬁcant effect of the plasma
albumin on acid–base status in the physiological approach.
This is not the case, as we have to adjust the anion gap for the
plasma albumin.1 Indeed, after this adjustment there is no
effect of albumin on the metabolic acid–base component. In
the clinical case example 2, the authors give the impression
that the physiological approach acknowledges a metabolic
alkalosis and the physicochemical approach only diagnoses a
hypoalbuminemic alkalosis. This is probably not true. A
decrease in plasma albumin level by 1 g/dl usually results in
an increase in bicarbonate level by 2.8mmol/l.3 Accordingly,
with a serum albumin level of 1.5mmol/l, the expected serum
bicarbonate level in this case will be 24þ 3 2.8
(8.4)¼ 32.4mmol/l. The patient’s serum bicarbonate is higher
(35mmol/l), probably because of an additional metabolic
alkalosis caused by the low potassium level of 3.2mmol/l. In
this context, the two approaches are therefore less different
than the authors suggest. The fact that the secondary DPaCO2
is not deﬁned in metabolic acidosis and alkalosis according to
the physicochemical approach1 is probably the most im-
portant limitation of this method, as additional respiratory
disturbances may be missed.
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The Authors Reply: We respectfully disagree with the
comments made by Dr Berend.1 The study he quoted to
counter our ‘assumption that the chloride level is normal in
high anion gap acidosis’ failed to detect absolute hypochlor-
emia in patients with this condition.2 Thus, normochloremic
acidosis is an appropriate and standard term for high anion
gap acidosis. This term allows differentiation of high anion
gap acidosis from the normal anion gap acidosis that features
hyperchloremia.
The need to adjust the plasma anion gap for the anionic
charge of plasma albumin, a simple computation performed
routinely by clinicians, is unrelated to the proposed effect of
albumin itself on acid–base status. As stated in our paper,3
there is no evidence that the body, and in particular, the liver,
regulates albumin to maintain acid–base balance. A role of
albumin itself in the regulation of acid–base status is accepted
by neither the physiological nor the base-excess approach.
Dr Berend claims that our assessment of example 2 is pro-
bably incorrect because we did not consider that a decrease in
plasma albumin by 1 g/dl results in an increase in bicarbonate
by 2.8mmol/l. As this claim is based on a simple associative
relationship,4 it provides no support for a cause-and-effect
relationship of albumin to plasma bicarbonate.
Finally, the lack of deﬁnition of the secondary ventilatory
response to metabolic acid–base disorders is indeed one of the
limitations of the physicochemical approach, but certainly not
its most serious drawback, as Dr Berend asserts.
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